AHFS Drug Information®

2020, 2021, 2022, 2023 Doody's Core Titles List Selection I 5-Star Rating from Doody's Review Service

AHFS DI is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients.

Benefits that are unique to AHFS DI include:

  • The only remaining original federal compendium whose authority for establishing accepted medical uses includes the broadest scope of drugs and indications under Medicaid, Medicare Part D, and more.
  • The only drug information resource with content developed by a professional editorial and analytical staff of pharmacists for a not-for-profit scientific organization.

2023 Edition Updates

AHFS 3D Book
  • Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
  • The latest information on the changing landscape of predominant COVID-19 subvariants and its effects on COVID therapeutics, including updated mRNA vaccine formulations, changes in emergency use authorization (EUA) status, and updated recommendations from the Infectious Diseases Society of America (IDSA), and the National Institutes of Health (NIH)
  • Contemporary topics such as new RSV treatments and vaccines, safety issues associated with the glucagon-like peptide 1 (GLP-1) agonists, novel orphan drugs, biosimilars, and more
  • Inclusion of Standardize4Safety concentration standards for IV and oral liquid drugs
+ View all updates
  • New content on gene therapies for the treatment of cancers and certain inherited disorders
  • The latest information from FDA safety communications regarding opioid pain medications and stimulant drugs
  • Newly published information on breakthrough oncology drugs approved as part of the FDA’s accelerated approval program
  • Expanded content on off-label uses, real-world data, and long-term clinical data
  • Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
  • Addition of 60 new molecular entities (NMEs) or new therapeutic biological products approved since January 2023

AHFS Clinical Drug Information App

AHFS CDI DigitalAHFS CDI expands your access to real-time drug and safety updates by linking directly and in context to 20 additional specialty databases. Easily switch between concise, direct point-of-care, actionable drug information with AHFS DI Essentials, or the full database contents of AHFS Drug Information.

With AHFS CDI you can:

  • Have constant access to all the latest updates— including drug shortages information
  • Toggle between a quick summary of essentials and a comprehensive monograph
  • Review compatibility matrices for patient care at the bedside
  • View seamlessly incorporated FDA safety data

Ways to Access Content

Reviews and Testimonials

...includes a collection of drug monographs for virtually every single drug entity available in the U.S. Jennifer L. Colon, PharmD, MS, MBA
...access quickly and easily, the specific guidance needed to prescribe and monitor drug therapy safely and effectively. Laurence A. Goldberg

Licensing Information

AHFS Drug Information® and AHFS DI® Essentials™ Database can be licensed by healthcare information system developers in formats and with content areas specific to organizational requirements. Content is updated monthly and available in XML.

Digital Access

AHFS CDI, seamlessly incorporates current drug shortages information and real-time drug and safety updates. You can easily switch between concise, direct point-of-care, actionable drug information with AHFS DI Essentials, or the full database contents of AHFS Drug Information.